Get started
AnaptysBio, Inc.AnaptysBio, Inc.AnaptysBio, Inc.

AnaptysBio, Inc.

No trades
No trades
OverviewFinancialsDocumentsNewsCommunityTechnicalsForecastsSeasonalsOptionsETFs
Full chart
Full chart

Compare with AnaptysBio, Inc.



Key stats


Market capitalization
‪1.60 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−0.86 USD
Net income (FY)
‪−13.23 M‬ USD
Revenue (FY)
‪234.60 M‬ USD
Shares float
‪27.63 M‬
Beta (1Y)
0.83

Latest earnings


Last report date
Sep 11, 2026
Report period
Q2 2026
EPS
−0.47 USD
Revenue
‪13.34 M‬ USD

Employees


Employees (FY)
104
Change (1Y)
−32−23.53%
Revenue / Employee (1Y)
‪2.26 M‬ USD
Net income / Employee (1Y)
‪−127.23 K‬ USD

Company info


Sector
Health Technology
Industry
Biotechnology
CEO
Daniel R. Faga
Website
anaptysbio.com
Headquarters
San Diego
Founded
2005
IPO date
Jan 26, 2017
ISIN
US0327241065
CUSIP
032724106
FIGI
BBG0026ZDHR0
Identifiers
ISIN US0327241065
CFI code
ESVUFR
AnaptysBio, Inc. is a clinical-stage biotechnology company, which engages in delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. The firm’s product pipeline includes Rosnilimab, ANB033, ANB101, Jemperli, and Imsidolimab. It operates through the Biopharma and Royalty Management segments. The Biopharma segment focuses on the development and potential commercialization of innovative immunology therapeutics for autoimmune and inflammatory diseases. The Royalty Management segment manages the financial collaboration for Jemperli with GSK and for imsidolimab with Vanda. The company was founded by Andrew B. Cubitt, William J. Boyle, Kevin J. Kinsella, and Nicholas B. Lydon in November 2005 and is headquartered in San Diego, CA.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Ideas



See all ideas 

Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Seasonals


Displays a symbol's price movements over previous years to identify recurring trends.

ETFs holding the stock


XBI
State Street SPDR S&P Biotech ETF
Weight0.42%
Market value‪44.63 M‬
IWM
iShares Russell 2000 Index Fund
Weight0.04%
Market value‪27.48 M‬
IBB
iShares Biotechnology ETF
Weight0.11%
Market value‪11.21 M‬
PBE
Invesco Biotechnology & Genome ETF
Weight2.67%
Market value‪10.83 M‬
IWO
iShares Russell 2000 Growth Fund
Weight0.07%
Market value‪10.00 M‬
BRES
Burney U.S. Equity Select ETF
Weight1.24%
Market value‪8.23 M‬
FYC
First Trust Small Cap Growth AlphaDEX Fund
Weight0.55%
Market value‪7.70 M‬
BRNY
Burney U.S. Factor Rotation ETF
Weight1.18%
Market value‪7.09 M‬
VTWO
Vanguard Russell 2000 ETF
Weight0.03%
Market value‪5.92 M‬
SCHA
Schwab U.S. Small-Cap ETF
Weight0.02%
Market value‪5.49 M‬
PSC
Principal U.S. Small-Cap ETF
Weight0.20%
Market value‪5.44 M‬

Explore more ETFs 

Frequently asked questions


The current price of ANAB is 53.87 USD — it has decreased by −2.34% in the past 24 hours. Watch AnaptysBio, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange AnaptysBio, Inc. stocks are traded under the ticker ANAB.
ANAB stock has fallen by −5.23% compared to the previous week, the month change is a −7.10% fall, over the last year AnaptysBio, Inc. has showed a 254.77% increase.
We've gathered analysts' opinions on AnaptysBio, Inc. future price: according to them, ANAB price has a max estimate of 95.00 USD and a min estimate of 75.00 USD. Watch ANAB chart and read a more detailed AnaptysBio, Inc. stock forecast: see what analysts think of AnaptysBio, Inc. and suggest that you do with its stocks.
ANAB reached its all-time high on Feb 20, 2018 with the price of 89.32 USD, and its all-time low was 6.67 USD and was reached on Nov 8, 2019. View more price dynamics on ANAB chart.
See other stocks reaching their highest and lowest prices.
ANAB stock is 4.77% volatile and has beta coefficient of 0.83. Track AnaptysBio, Inc. stock price on the chart and check out the list of the most volatile stocks — is AnaptysBio, Inc. there?
Today AnaptysBio, Inc. has the market capitalization of ‪1.60 B‬, it has decreased by −2.53% over the last week.
Yes, you can track AnaptysBio, Inc. financials in yearly and quarterly reports right on TradingView.
AnaptysBio, Inc. is going to release the next earnings report on Nov 10, 2026. Keep track of upcoming events with our Earnings Calendar.
ANAB earnings for the last quarter are −0.47 USD per share, whereas the estimation was −0.47 USD resulting in a 0.00% surprise. The estimated earnings for the next quarter are −0.05 USD per share. See more details about AnaptysBio, Inc. earnings.
AnaptysBio, Inc. revenue for the last quarter amounts to ‪13.34 M‬ USD, despite the estimated figure of ‪14.06 M‬ USD. In the next quarter, revenue is expected to reach ‪16.13 M‬ USD.
ANAB net income for the last quarter is ‪−52.88 M‬ USD, while the quarter before that showed ‪49.61 M‬ USD of net income which accounts for 0.00% change. Track more AnaptysBio, Inc. financial stats to get the full picture.
No, ANAB doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Sep 13, 2026, the company has 104 employees. See our rating of the largest employees — is AnaptysBio, Inc. on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. AnaptysBio, Inc. EBITDA is ‪43.23 M‬ USD, and current EBITDA margin is 21.45%. See more stats in AnaptysBio, Inc. financial statements.
Like other stocks, ANAB shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade AnaptysBio, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So AnaptysBio, Inc. technincal analysis shows the sell today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating AnaptysBio, Inc. stock shows the buy signal. See more of AnaptysBio, Inc. technicals for a more comprehensive analysis.